Blydt-Hansen, Ingrid, et al. “Emicizumab in Severe Hemophilia A: Clinical and Patient Determinants of Transition Within a Standardized Program”. Journal of Hematology, vol. 14, no. 5, Jan. 2025, pp. 257-61, https://doi.org/10.14740/jh2113.